Revance Highlights RHA Dynamic Volume Mid-Face FDA Approval at Virtual Desk Side

Revance Aesthetics hosted a virtual desk side with Lesley Clark-Loeser, MD, to discuss the recent US Food and Drug Administration (FDA) approval of RHA Dynamic Volume for cheek augmentation and correction of age-related mid-face contour deficiencies in adults aged 22 years and older.

The approval expands the indications of the Teoxane RHA Collection, positioning it as the first hyaluronic acid (HA) filler portfolio approved across nasolabial folds, perioral lines, lips, and the mid-face. RHA Dynamic Volume was previously known as RHA for MEPI.

According to the presenters, the platform is built on Preserved Network Technology (PNT), a manufacturing process designed to limit chemical modification of HA chains. This approach is intended to produce a gel with both stretch and strength, allowing it to adapt to dynamic facial movement while maintaining structural integrity. Clinical trial data referenced during the session indicated that more than 94% of treated patients reported natural-looking results at 1 year.

Dr. Clark-Loeser described an injection approach tailored to the new indication, emphasizing multi-layer placement within superficial and deep fat pads of the lateral mid-face. She noted that this technique may help avoid mid-cheek fullness during animation and instead support more balanced contour restoration. Typical treatment volumes were described as approximately 1 mL per side.

She also positioned the broader RHA portfolio as a “toolkit” for individualized treatment, with product selection based on anatomic region and patient age-related changes, including volume loss associated with menopause or GLP-1 RA–related weight reduction.